Mareque M, Montesinos P, Font P, et al. Clinicoecon Outcomes Res. 2021;13:263–277.
Page 271, Results, Base Case, second line from the bottom, the text “€ 15,134” should read “€ 151,434”.
The authors apologize for this error.
. 2021 Jul 14;13:645. doi: 10.2147/CEOR.S328284
Cost-Effectiveness Analysis of Gemtuzumab Ozogamicin for First-Line Treatment of Patients with Cd-33 Positive Acute Myeloid Leukaemia in Spain [Corrigendum]
Received 2021 Jul 7; Accepted 2021 Jul 7; Collection date 2021.
© 2021 Mareque et al.
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
PMCID: PMC8286780 PMID: 34285523
This corrects the article "Cost-Effectiveness Analysis of Gemtuzumab Ozogamicin for First-Line Treatment of Patients with Cd-33 Positive Acute Myeloid Leukaemia in Spain" on page 263.